WallStSmart
PHVS

Pharvaris BV

NASDAQ: PHVS · HEALTHCARE · BIOTECHNOLOGY

$29.95
-1.71% today

Updated 2026-06-05

Market cap
$2.15B
P/E ratio
P/S ratio
EPS (TTM)
$-3.14
Dividend yield
52W range
$16 – $33
Volume
0.3M

Pharvaris BV (PHVS) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-3.92M$-6.68M$-21.50M$-44.60M$-67.16M$-93.05M$-120.13M$-137.07M
Capital expenditures$13476.00$13476.00$42977.00$130032.00$124296.00$89984.00$538086.00$164619.00
Depreciation$549.00$549.00$7401.00$77370.00$152941.00$257551.00$269562.00
Stock-based comp$100745.00$116147.00$1.59M$8.20M$11.35M$10.66M$16.21M$19.05M
Free cash flow$-3.93M$-6.69M$-21.54M$-44.73M$-67.29M$-93.14M$-120.67M$-137.24M
Investing cash flow$-13476.00$-13476.00$-42977.00$-130032.00$-124296.00$-89984.00$-538086.00
Financing cash flow$4.51M$21.63M$101.20M$143.67M$8.65M$325.39M$2.68M
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does PHVS generate?

PHVS produced $-137.24M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PHVS's balance sheet healthy?

PHVS holds $291.68M in cash and equivalents against — in long-term debt, on $271.27M of shareholder equity. That debt is best read against the cash flow the business throws off each year.